Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FIIN-2 + Fulvestrant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FIIN-2 | FIIN 2|FIIN2 | FGFR Inhibitor (Pan) 26 | FIIN-2 is a selective, irreversible Fgfr inhibitor with activity against Fgfr mutations that confer resistance to first-generation Fgfr inhibitors, potentially resulting in decreased tumor cell proliferation (PMID: 25349422). | |
Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 29 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|